What is ProLynx?
ProLynx is a biotechnology firm focused on pioneering ultra-long-acting pharmaceutical treatments for obesity and associated metabolic disorders. Leveraging a proprietary half-life extension technology, the company aims to deliver more consistent and tolerable long-term therapeutic options. This innovative approach is designed to optimize pharmacokinetics, offering a potential paradigm shift in chronic disease management.
How much funding has ProLynx raised?
ProLynx has raised a total of $70.4M across 3 funding rounds:
Debt
$150K
Debt
$207K
Series A
$70M
Debt (2020): $150K with participation from PPP
Debt (2021): $207K led by PPP
Series A (2025): $70M supported by 5AM Ventures, OrbiMed, and Monograph Capital
Key Investors in ProLynx
5AM Ventures
Five AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies, fund rigorous science and help bring new therapies and technologies to patients.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains. The firm manages capital across biopharmaceuticals, medical devices, digital health platforms, diagnostics, and healthcare services, bringing together investment professionals with extensive experience in life sciences and healthcare business development.
Monograph Capital
Monograph Capital is focused on finding and funding innovative life sciences companies to help translate promising science into life-changing treatments for patients globally. The firm operates with a transatlantic team that sources leading scientific innovations and supports the development of strong companies.
What's next for ProLynx?
With this substantial capital infusion, ProLynx is poised to accelerate its development pipeline and advance its proprietary portfolio towards clinical validation and potential commercialization. The strategic backing from prominent life science investors suggests a strong market appetite for ProLynx's innovative approach to metabolic disease treatment. Future endeavors will likely focus on expanding research and development efforts, potentially initiating new clinical trials, and solidifying strategic partnerships to bring these advanced therapies to patients.
See full ProLynx company page
